NCT06184750View on ClinicalTrials.gov

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 27, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

September 30, 2028

Conditions
Breast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In SituEstrogen Receptor-Positive Breast Carcinoma
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Mammography

Undergo mammography

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Tamoxifen

Given PO

Trial Locations (11)

29425

RECRUITING

Medical University of South Carolina, Charleston

44106

NOT_YET_RECRUITING

Case Western Reserve University, Cleveland

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

60611

RECRUITING

Northwestern University, Chicago

60612

RECRUITING

University of Illinois College of Medicine - Chicago, Chicago

63110

RECRUITING

Washington University School of Medicine, St Louis

66160

RECRUITING

University of Kansas Cancer Center, Kansas City

77030

RECRUITING

M D Anderson Cancer Center, Houston

85719

RECRUITING

University of Arizona Cancer Center - Prevention Research Clinic, Tucson

02115

RECRUITING

Brigham and Women's Hospital, Boston

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH